Lilly signs up to $1.3 billion deal with Superluminal Medicines to develop obesity medicines

By Thomson Reuters Aug 14, 2025 | 8:15 AM

(Reuters) -Eli Lilly has signed a deal worth up to $1.3 billion with privately held Superluminal Medicines to discover and develop drugs targeting cardiometabolic diseases and obesity, Superluminal said on Thursday.

(Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)